Sorrento And Mabpharm Get ‘Biobetter’ Infliximab Approval In China

Plans To File Biosimilar With Improved Safety Profile In US And Europe This Year

 
• By Dave Wallace
  
China Flag Thumbs Up
China’s NMPA has approved the infliximab “biobetter” • Source: Alamy

More from Biosimilars

More from Products